PD98059

Catalog No.S1177

PD98059 Chemical Structure

Molecular Weight(MW): 267.28

PD98059 is a non-ATP competitive MEK inhibitor with IC50 of 2 μM in a cell-free assay, specifically inhibits MEK-1-mediated activation of MAPK; does not directly inhibit ERK1 or ERK2.

Size Price Stock Quantity  
In DMSO USD 134 In stock
USD 147 In stock
USD 470 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 49 Publications

10 Customer Reviews

  • Nature, 2016, 537(7620):422-427.. PD98059 purchased from Selleck.

     

    Melanoma cell viability and in vivo growth by cyclindependent kinase 2/4 inhibition. Western blot analysis for c-Jun, phosphorylated-ERK1/2 (Thr202/Tyr204) (p-ERK1/2), and total ERK1/2 protein levels was done for human melanoma cell lines treated with the BRAFV600E inhibitor GDC-0879 (1 μM), or MEK inhibitors CI-1040 (1 μM), U0126 (1 μM), and PD98059 (10 μM) for 18 hours.

    J Natl Cancer Inst 2012 104(21), 1673-9. PD98059 purchased from Selleck.

  •  

    Melanoma cell viability and in vivo growth by cyclindependent kinase 2/4 inhibition. In vivo growth of LOXIMVI xenografts in athymic nude Foxn1nu mice is shown. Tumors were allowed to grow to a maximum volume of 250 mm3, and the mice were subsequently treated daily at the indicated dose levels with CDK2/4 inhibitors by intraperitoneal injection in combination with a BRAFV600E- or MEK-inhibitor. CDK2/4 inhibitor (CVT-313/indolocarbazole CDK4-I) treatment sensitizes tumors to GDC-0879 and CI1040.

    J Natl Cancer Inst 2012 104(21), 1673-9. PD98059 purchased from Selleck.

    effect of ERK1/2 inhibitor PD98059 (1, 5, and 10 μM) on SRP72 protein expression was evaluated on Jurkat cells stimulated with rhIL-1. The cells were harvested at 0,120, and 240 min, and the protein expression was verified by WB using antibodies against human SRP72, human SRP54 (nonphosphorylated SRP protein), and humanGAPDHas constitutive protein.Adecreased SRP72 expression at 10 μM and 240 min was found.

     

     

    J Biol Chem 2010 285, 32824-32833. PD98059 purchased from Selleck.

  • C, effect of ERK1/2 inhibitor PD98059 (1, 5, and 10 μM) was evaluated in SRP72-immunoprecipitated cell lysates. WB using anti-phosphoserine antibody showed a decreased SRP72 band when used as the inhibitor at concentrations of 1 μM at 240 min, 5 μM at 120 min, and 10 μM at 120 and 240 min (lanes 3, 5, 8, and 9). D, results were analyzed and RUA illustrated, finding significant results at 1 μM at 240 versus 0, 5 μM at 120 versus 0, and 10 μM at 120 versus 0 min.

     

     

    J Biol Chem 2010 285, 32824-32833. PD98059 purchased from Selleck.

    We used real time RT-PCR to investigate the effects of PD98059 on SRP72 mRNA expression. All the samples were treated under the same experimental conditions used in protein tests done by WB, and phosphorylation was measured indirectly by IP-WB. The results did not show significant changes on the mRNA expression of SRP72 after the treatment with these inhibitors.

     

     

    J Biol Chem 2010 285, 32824-32833. PD98059 purchased from Selleck.

  •  

    Activation of a TLR2eERK1/2 pathway in MDDC. (C) MDDC were either untreated or treated with C. pneumoniae alone or in the presence of the ERK1/2 inhibitor PD98059 for 48 h. IL-12p70 and IL-10 release in culture media was assessed by ELISA. (D) MDDC were treated as in panel C for 48 h and then cocultured with purified allogeneic CD3t T cells. On day 12, supernatants were collected, and secreted cytokines were measured by ELISA.

    Microbes Infect 2013 15, 105-14. PD98059 purchased from Selleck.

    HepG2 cells, “Pnt-2” primary HCC cells or THLE-2 normal liver cells were pretreated with PD-98059 (1 mM) or MEK-162 (“MEK”, 1 mM) for 1 h prior toWAY-600 (“WAY”, 100 nM) treatment, after applied period, cell viability and apoptosis were tested by MTT assay (F and H).

    Biochem Biophys Res Commun, 2016, 474(2):330-7.. PD98059 purchased from Selleck.

  • Collagen I and α-SMA are conducive for S. aureus adhesion to and invasion into BMFBs. BMFBs were treated with PD98059 2 h before the addition of 5 ng/ml TGF-β1; 24 h later, the adhesion (A) and invasion (B) assays were performed as previously described. The results are expressed as the mean cfu/ml ± SD from experiments performed in triplicate (*P < 0.05, **P < 0.01).

    Microb Pathog, 2017.. PD98059 purchased from Selleck.

    After starved in serum-free medium for 24h,T47D cells incubated with the indicated concentrations of  PD98059 for 3h,followed by 20-minute  stimolation of 100ng/ml EGF.

     

    2010 Dr. Zhang of Tianjin Medical University. PD98059 purchased from Selleck.

Purity & Quality Control

Choose Selective MEK Inhibitors

Biological Activity

Description PD98059 is a non-ATP competitive MEK inhibitor with IC50 of 2 μM in a cell-free assay, specifically inhibits MEK-1-mediated activation of MAPK; does not directly inhibit ERK1 or ERK2.
Features Does not inhibit c-Raf phosphorylated MEK1.
Targets
MEK1 [1]
(Cell-free assay)
2 μM
In vitro

PD98059 inhibits either basal MEK1 or a partially activated MEK produced by mutation of serine at residues 218 and 222 to glutamate (MEK-2E) with IC50 of 2 μM. PD98059 does not inhibit the MAPK homologues JNK and P38. PD98059 is highly selective against MEK, as it does not inhibit a number of other kinase activities including Raf kinase, cAMP-dependent kinase, protein kinase C, v-Src, epidermal growth factor (EGF) receptor kinase, insulin receptor kinase, PDGF receptor kinase, and phosphatidylinositol 3-kinase. PD98059 inhibits PDGF-stimulated activation of MAPK and thymidine incorporation into 3T3 cells with IC50 of ~10 μM and ~7 μM, respectively. [1] PD98059 potently prevents the activation of MEK1 by Raf or MEK kinase with IC50 of 4 μM, and weakly inhibits the activation of MEK2 by Raf with IC50 of 50 μM. PD98059 does not inhibit the activation of MEK homologues MKK4 and RK kinase that participate in stress and interleukin-1-stimulated kinase cascades in KB and PC12 cells, and the activation of p70 S6 kinase by insulin or epidermal growth factor in Swiss 3T3 cells. [2] PD98059 completely blocks the nerve growth factor (NGF)-induced differentiation of PC12 cells without altering cell viability. [3] PD98059 inhibits the proliferation of RAW264.7 cells in the culture containing RANKL in a dose-dependent manner, resulting in an apparent decrease of TRAP-positive cells. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
H1355 NEG2VHFHfW6ldHnvckBCe3OjeR?= MXWyOUDPxE1? NW\ZRY97OSCq NEjm[XhjdHWwdIOgeIhmKEKdYW3QMYlv\HWlZXSgbY5kemWjc3WgbY4heGixc4Doc{1EcGtzIHHu[EBxcG:|cHjvMWVTUyCneIDy[ZN{cW:w MkS0NlU4PjlzOEG=
MCF-7  MljSSpVv[3Srb36gRZN{[Xl? M2juN|ExKM7:TR?= NVvrPHN[OSCq NEjDVWJqdmirYnn0d{BKVC1zOD3lcohidmOnZDDj[YxtKG2rZ4LheIlwdg>? M4HOPVI2PzJ5MEGx
HepG2  MUnGeY5kfGmxbjDBd5NigQ>? MkfiNVAh|ryP NEnYd482KGh? MnLUZoxw[2u|IIDoc5NxcG:{eXzheIVlKE2DUFvzJIlv\HWlZXSgZpkh\XixZ3Xuc5V{KFSJRj5OtlE> NYfiV4wyOjV3NkC0PFg>
HepG2  NUP4WXA{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvBZowzOCEQvF2= MYKyOEBp NFjXeGd{fXCycnXzd4V{KFSJRj5OtlEucW6mdXPl[EBk\WyuIIDyc4xq\mW{YYTpc44h[W6mIHnueoF{cW:w M1\X[FI2PTZyNEi4
MDA-MB-231 M3nSbmZ2dmO2aX;uJGF{e2G7 NHXoOFIzPSEQvF2= NHexXmIzNTNiaB?= NVvGV5Fw\GWlcnXhd4V{KHBvRWLLNU8zKGGwZDDTNVAxSTRiZYjwdoV{e2mxbh?= NGHkR2EzPTV3NUi3OS=>
SW480 MnLnSpVv[3Srb36gRZN{[Xl? M2jkb|IxyqEQvF2= M1TSOVHDqGh? M4i5RpJm\HWlZYOgeIhmKGW6cILld5Nqd25ib3[gRXRHOyCycn;0[Ylv MoPzNlU1PDd6MU[=
HCT-15 Ml20SpVv[3Srb36gRZN{[Xl? M4nwR|EhcA>? MmTaZZR1\W63YYTld{BRT0V{LXnu[JVk\WRicHjvd5Bpd3K7bHH0bY9vKG:oIFXyb:Kh MWKyOVQ{OTR{NR?=
HCT-15 MXXBdI9xfG:|aYOgRZN{[Xl? NHHLW2IyKGh? NHXCTmpi[m:uaYPo[ZMhfGinIIDyc5Rm[3SrdnWg[YZn\WO2czDv[kBRT0V{wrDh[4FqdnO2IHP1doN2dWmwLXnu[JVk\WRiYYDvdJRwe2m| NIjTc2czPTR|MUSyOS=>
786-O MYDBdI9xfG:|aYOgRZN{[Xl? MoPnOVDDqM7:TR?= NXTDbIpvOjRiaB?= MY\wc5RmdnSrYYTld:KhfGinIIDyc{1ieG:ydH;0bYMh\W[oZXP0d{Bw\iCQQx?= MnPPNlQ2ODh2N{[=
A498 M1zT[mFxd3C2b4Ppd{BCe3OjeR?= NXXXR3l6PTEEoN88US=> NE\hTZQzPCCq MWnwc5RmdnSrYYTld:KhfGinIIDyc{1ieG:ydH;0bYMh\W[oZXP0d{Bw\iCQQx?= NGrvT4gzPDVyOES3Oi=>
NHBE MoDvSpVv[3Srb36gRZN{[Xl? MnfmNk8zOCEQvF2= NXvVb|c2OiCq NU\PZ2dy[XS2ZX71ZZRmeyCLTD2zN{B{fGmvdXzheIVlKEO[Q1y4M2lNNThic3XjdoV1cW:w M{O2TFI1PDd7NUK2
A375 NV3WWGI2S2WubDDJcpZie2mxbjDBd5NigQ>? MV6xNQKBmzJyINM1US=> MVGyOEBp M4PqO5Jm\HWlZYOgcYVt[W6xbXGgZ4VtdCCrbo\hd4lwdg>? MV6yOFQ3PjB|Nh?=
HBMEC NFm0NGpHfW6ldHnvckBCe3OjeR?= MkjHNVAh|ryP MUGxJIg> Moe0Zoxw[2u|IG\FS2YucW6mdXPl[EBGeGiDMjDlfJBz\XO|aX;u MYeyOFQ2QDl6Mh?=
HPAEpiCs  NUHyNVJ1TnWwY4Tpc44hSXO|YYm= NVTjS3dsOzBizszN NH\GcWEyKGh? NHjrUJJqdmirYnn0d{BVVkZvzsGgd5RqdXWuYYTl[EBxPDJxcES0JG1CWEticHjvd5Bpd3K7bHH0bY9v M370flI1PDRzOEew
BeWo NUfvTXR7TnWwY4Tpc44hSXO|YYm= M3HoOlExyqEQvF2= NHvXfHYzKGh? M3nFTYlvcGmkaYTzJGVTUzFxMh?= NYLvOYdtOjR2M{O4OFY>
PC3  M1v2XmFxd3C2b4Ppd{BCe3OjeR?= M4\tbVUxKM7:TR?= NE\aR4sxNjViaB?= MmKybY5pcWKrdIOgUWh[NTR2OT3pcoR2[2WmIHHwc5B1d3Orc9Mg MY[yOFQzPDh6OR?=
HGC-27 NFjzTlhCeG:ydH;zbZMhSXO|YYm= MXexJOK2VQ>? NWrOT|RSOSCq NUmxcnUze3WycILld5NmeyCUQVSwNFEheGy3czDNT{0zOjB4LXnu[JVk\WRiY3XscEB3cWGkaXzpeJkhdG:|cx?= MViyOFQyPjN2OR?=
MCF-7 MWPGeY5kfGmxbjDBd5NigQ>? M3XPdVExyqEQvF2= MnjoNVAwOzBibXnu NWfZR4dbemWmdXPld{B1cGViVWTQMYRmeGWwZHXueEBGWkticHjvd5Bpd3K7bHH0bY9v NH\CS5gzPDN7MEixPS=>
HUVECs NIO4T2VHfW6ldHnvckBCe3OjeR?= M2O4d|ExyqEQvF2= MVSxJIg> MYnpcohq[mm2czD0bIUhUESOIILl[JVk\WRiQ1;YMVIh\XiycnXzd4lwdiCjbnSgVGdKNTJicnXs[YF{\Q>? MYCyOFM5PTFyOR?=
HeLa NUnl[4hCTnWwY4Tpc44hSXO|YYm= M3HEO|UxKM7:TR?= NU\rVIt4OC53IHi= NUHtV4lH[myxY3vzJHRTYC1zIH71Z4xm[XJibXnndoF1cW:wIHHu[EBVYE6LUDDkc5dvNXKnZ4XsZZRqd25? NYfrVpI{OjR|N{[4Nlc>
HL-60  M3vJR2Z2dmO2aX;uJGF{e2G7 M3rqVFExNzJyIN88US=> MWixJIg> NHP6cXZqdmirYnn0d{B1cGYEoF6uJINpcW6nboPpd4V5fHKjY4VCpIlv\HWlZXSg[Iln\mW{ZX70bYF1cW:wIHnueI8h\3KjboXsc4N6fGW| NEH3TVYzPDN3N{CyNC=>
HL-60 MkXBSpVv[3Srb36gRZN{[Xl? MYKyJOK2VQ>? NXTmUI53OTZiaB?= NET3cHNFVVOR NV31TGhZcW6qaXLpeJMhfGinIHHzd49kcWG2aX;uJI9nKHCVNkKxJHJi\i1zIHHu[EBPTkGWY{OsJIFv\CC2aHWgVmEucW6mdXPl[EBxcG:|cHjvdplt[XSrb36gc4YhdnWlbHXhdkBPTkGWY{O= MoDkNlQ{OzByNki=
HEK 293 NVzKRlJKTnWwY4Tpc44hSXO|YYm= NESzUpkyOCEQvF2= MXG1JIg> MmqySG1UVw>? NFnDWZFqdmirYnn0d{BYdnRvaX7keYNm\CEQsj3jZZRmdmmwL2TDSlQh[WO2aY\peJkh[W6mIH71Z4xm[XJizsKtZ4F1\W6rbjDhZ4N2dXWuYYTpc44> MUWyOFMzPDN4Nh?=
HEK 293 MXvGeY5kfGmxbjDBd5NigQ>? MY[xNEDPxE1? NIfmUWc2KGh? M4ruZWROW09? M3P0[5N2eHC{ZYPz[ZMhfGinIFPSWEBi[3Srdnn0fS=> NF\nO3gzPDN{NEO2Oi=>
SW480 MkLESpVv[3Srb36gRZN{[Xl? NILRXVcyOCEQvF2= NIfPbmUzOCCq NEnqPG1FVVOR M1HNSZN2eHC{ZYPz[ZMhfGinIFPSWEBi[3Srdnn0fS=> NFTxZYgzPDN{NEO2Oi=>
HCSMCs NETEcGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jsVlExKM7:TR?= NXO4[lRCOjRiaB?= NIj5VZBjdG:la4OgSmFDWDRvaX7keYNm\CCKQ1HTUWMheHKxbHnm[ZJifGmxbh?= M4HOZ|I1OzF{M{ix
PANC-1 NVXpUGxQTnWwY4Tpc44hSXO|YYm= NW\tWohuOjBizszN MV20PEBp NFfpOHpqdmirYnn0d{B1cGViZYjwdoV{e2mxbjDv[kDPnD[GIHnuJJJme3CxboPlJJRwKHSqZTDQVGFT|rUEoHHnc45qe3UEoB?= M1fwNVI1Ojl2MUOz
A549 M1XSWmZ2dmO2aX;uJGF{e2G7 M{n5bFMxKM7:TR?= NF;T[lkxNjViaB?= NHLqXYVFVVOR NHrTNFRqdmirYnn0d{B1cGVidHjyc41jcW5vaX7keYNm\CCLTD24M2NZS0x6LVz1Z{Bi[3Srdnn0fS=> MonLNlQzPzd4OU[=
A549 MlPzSpVv[3Srb36gRZN{[Xl? NFHx[XU{OCEQvF2= MkntNE42KGh? NEX2WHJFVVOR NHiyblVqdmirYnn0d{B1cHKxbXLpck1qdmS3Y3XkJGMwTUKSzsKgWIhzOjN3wrDwbI9{eGixconsZZRqd25? NF;KXpozPDJ5N{[5Oi=>
MC-3 MnLkRZBweHSxc3nzJGF{e2G7 NXvtfmdDOTBizszN M1y3NlI1KGh? MVLwc5RmdnSrYYTl[EBOTVOFLXnu[JVk\WRiYYDvdJRwe2m|IHnuJEBk\Wyucx?= MXyyOFI4ODV{Mx?=
Raji  NHzvb2xHfW6ldHnvckBCe3OjeR?= NVjHcHF{OTBizszN NVnzS2RbOSCq NI[1N45jdG:la4OgbJNDSU[IIHnu[JVk\WRiRYLrNU8zKHCqb4PwbI9zgWyjdHnvci=> MnrHNlQzPjl4M{C=
Raji  NULkVZo3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3HUO|ExKM7:TR?= NFjLPGMyKGh? M3T1PIlvcGmkaYTzJJRp\SCkYYPhcEBweiCqc1LBSmYue3SrbYXsZZRm\CClZXzsJJBzd2yrZnXyZZRqd25iYX7kJJZq[WKrbHn0fS=> NHnwdWMzPDJ4OU[zNC=>
HT29 MXTGeY5kfGmxbjDBd5NigQ>? MoDaNVAh|ryP NUf4WFBEOiCq Mn7vbY5pcWKrdIOgc4YhUkGNMjygSXJMOS9{IHHu[EBUXEGWMzDwbI9{eGixconsZZRqd25? NWS3VY9OOjR{NkWyPVM>
HepG2 MWrBdI9xfG:|aYOgRZN{[Xl? MU[yNEDPxE1? MV6yOEBp M2\pfolvcGmkaYTzJGVTUzFxMjDwbI9{eGixconsZZRqd25iYX7kJIVvcGGwY3XzJHZDOS2rbnT1Z4VlKGGyb4D0c5Nqew>? MorENlQzPDd7MEm=
HepG2 M2PoOmZ2dmO2aX;uJGF{e2G7 NFi0ZYwzOCEQvF2= M1KyRlIhcA>? MnrM[Y5p[W6lZYOgWmIyNWmwZIXj[YQhTk:[T{PhJJRz[W6|Y4LpdJRqd26jbDDhZ5Rqfmm2eR?= M3vPZlI1OjR5OUC5
TE4 NGfjb4JHfW6ldHnvckBCe3OjeR?= MoG1NlAwPTBxMUCwJO69VQ>? M2j3c|Q5KGh? MYTEUXNQ NV3OZ|RmcW6qaXLpeJMheC2HcnugZY5lKHexcoTtZY5vcW5iZH;3cpJm\3WuYYTl[EBxNUGtdDDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M37obFI1OjR2MEKz
TE1 NF\IXJNHfW6ldHnvckBCe3OjeR?= MlzUNlAwPTBxMUCwJO69VQ>? M2XwOVQ5KGh? NVGxOJM{TE2VTx?= NWHrSIxQcW6qaXLpeJMheC2HcnugZY5lKHexcoTtZY5vcW5iZH;3cpJm\3WuYYTl[EBxNUGtdDDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NHj0[40zPDJ2NECyNy=>
KYSE30 NWrqRXpWTnWwY4Tpc44hSXO|YYm= MXKyNE82OC9zMECg{txO NG\JRYE1QCCq NFrKZmNFVVOR M4rCdolvcGmkaYTzJJAuTXKtIHHu[EB4d3K2bXHucolvKGSxd37y[Yd2dGG2ZXSgdE1Cc3RiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M4W0flI1OjR2MEKz
TE1 M4XuNmZ2dmO2aX;uJGF{e2G7 MofjOVAh|ryP MmO2OFghcA>? NIPOVndFVVOR MXT1dJJm\3WuYYTld{B1cGViZYjwdoV{e2mxbjDv[kBJVEFiY3zhd5MhUQ>? M3vqeFI1OjR2MEKz
TE3 M4D4bGZ2dmO2aX;uJGF{e2G7 M4rJfVUxKM7:TR?= Mn[2OFghcA>? M4TYcmROW09? MWX1dJJm\3WuYYTld{B1cGViZYjwdoV{e2mxbjDv[kBJVEFiY3zhd5MhUQ>? MWKyOFI1PDB{Mx?=
TE4 MnHoSpVv[3Srb36gRZN{[Xl? MX61NEDPxE1? M4TYZlQ5KGh? M3fFVWROW09? M4PwR5VxemWpdXzheIV{KHSqZTDlfJBz\XO|aX;uJI9nKEiOQTDjcIF{eyCL MVmyOFI1PDB{Mx?=
TE5 M4PHTGZ2dmO2aX;uJGF{e2G7 NGPHR4I2OCEQvF2= MYW0PEBp NXXWc3plTE2VTx?= NX\GXJl{fXC{ZXf1cIF1\XNidHjlJIV5eHKnc4Ppc44hd2ZiSFzBJINt[XO|IFm= NHe3NnozPDJ2NECyNy=>
KYSE30 NUjIRXZUTnWwY4Tpc44hSXO|YYm= M1zuTVUxKM7:TR?= M3u1NVQ5KGh? NV;EZ2FCTE2VTx?= NW\CXnhQfXC{ZXf1cIF1\XNidHjlJIV5eHKnc4Ppc44hd2ZiSFzBJINt[XO|IFm= M1XrNFI1OjR2MEKz
MKN7 MVLGeY5kfGmxbjDBd5NigQ>? MY[1NEDPxE1? MVm0PEBp M3WxT2ROW09? MlO1bY5kemWjc3XzJIV5eHKnc4Ppc44hd2ZiSFzBMWExOiCxcjDIUGEuSTJ2IH3vcIVkfWyncx?= MlfjNlQzPDRyMkO=
OE19 NY\xVnZsTnWwY4Tpc44hSXO|YYm= NG\pb4M2OCEQvF2= MnTsOFghcA>? Mk[zSG1UVw>? MW\pcoNz\WG|ZYOg[ZhxemW|c3nvckBw\iCKTFGtRVAzKG:{IFjMRU1COjRibX;s[YN2dGW| NYOzcINsOjR{NESwNlM>
KATOIII  MVjGeY5kfGmxbjDBd5NigQ>? M1nNc|UxKM7:TR?= M1r5ZlQ5KGh? M4nKeWROW09? MmixbY5kemWjc3XzJIV5eHKnc4Ppc44hd2ZiSFzBMWExOiCxcjDIUGEuSTJ2IH3vcIVkfWyncx?= MVmyOFI1PDB{Mx?=
NCI-N87  MojBSpVv[3Srb36gRZN{[Xl? NYHVXW05PTBizszN NH:0WI81QCCq NW\Ye|E5TE2VTx?= M2q3S4lv[3KnYYPld{BmgHC{ZYPzbY9vKG:oIFjMRU1CODJib4KgTGxCNUF{NDDtc4xm[3WuZYO= NHL6OJAzPDJ2NECyNy=>
NUGC3 MV3GeY5kfGmxbjDBd5NigQ>? NYr6NFJ{PTBizszN M3;QW|Q5KGh? NVvVU3lPTE2VTx?= NYjYNJk4cW6lcnXhd4V{KGW6cILld5Nqd25ib3[gTGxCNUFyMjDvdkBJVEFvQUK0JI1wdGWldXzldy=> NVHFZ4lFOjR{NESwNlM>
NUGC2 NH\TfWtHfW6ldHnvckBCe3OjeR?= M{\hO|UxKM7:TR?= MlL0OFghcA>? NX3KUXJGTE2VTx?= MVPpcoNz\WG|ZYOg[ZhxemW|c3nvckBw\iCKTFGtRVAzKG:{IFjMRU1COjRibX;s[YN2dGW| NF3LeGYzPDJ2NECyNy=>
SGC-7901  M3LwdWFxd3C2b4Ppd{BCe3OjeR?= NIj3fHozOCEQvF2= MoHYNlQhcA>? NH33W2dqdmirYnn0d{BEWC2vZXTpZZRm\CCjcH;weI9{cXN? M2rVWlI1OjRzM{Wx
MG-63 M1XseGZ2dmO2aX;uJGF{e2G7 MXiyNEDPxE1? NG\lfpYxNjViaB?= M1fq[IJtd2OtczD0bIUhS0hvaX7keYNm\CCyaH;zdIhwenmuYYTl[EBGVEtzIIDyc5RmcW5iZYjwdoV{e2mxbh?= NFnYR|kzPDJ|OU[0NC=>
ARPE-19 MY\GeY5kfGmxbjDBd5NigQ>? NWD5R443OjBizszN NY[2XFRCOC53IHi= MXHpcohq[mm2czDBdIVtcW5vaX7keYNm\CCyaH;zdIhwenmuYYTpc44hd2ZiRYLrJIFv\CCDa4S= M3T4fFI1OjJ5OUG4
CRL-2302 NXW0d|YxTnWwY4Tpc44hSXO|YYm= NEPmT|czOCEQvF2= MV2wMlUhcA>? NXO0cWE3cW6qaXLpeJMhSXCnbHnuMYlv\HWlZXSgdIhwe3Cqb4L5cIF1cW:wIH;mJGVzcyCjbnSgRYt1 MViyOFIzPzlzOB?=
MCF-7 MV\GeY5kfGmxbjDBd5NigQ>? MX[yNEDPxE1? NWLyVZRxOSCq NEfsO4Vi[m:uaYPo[ZMh\XiycnXzd4lwdiCxZjDwbI9{eGixconsZZRm\CCHUlugZ48ufHKnYYTt[Y51KHerdHigZ49vcnWpYYTl MUWyOFIyPjJ6OR?=
MCF-7 M{nIU2Fxd3C2b4Ppd{BCe3OjeR?= M2Hs[FIxKM7:TR?= NUXJOFJyOSCq NX3tOVFZcW6lcnXhd4V{KGOjc4Dhd4UuQSCnbor5cYUh[WO2aY\peJk> MnXPNlQzOTZ{OEm=
DLD-1  NETOO5JHfW6ldHnvckBCe3OjeR?= NXq3VVl6OjEEoN88US=> NHL3XVQ1QCCq NFvzXm5z\WS3Y3XzJJRp\SCETlnQN{BmgHC{ZYPzbY9vKHC{ZT30doVifGWmIIfpeIghPS2jenGt[GM> M{DMWVI1OjFzNUix
HT-29 NUXpVnluTnWwY4Tpc44hSXO|YYm= MViyNOKh|ryP NFfUe5U1QCCq Moq3doVlfWOnczD0bIUhSk6LUEOg[ZhxemW|c3nvckBxemVvdILlZZRm\CC5aYToJFUu[XqjLXTD M2\melI1OjFzNUix
7402 MYfBdI9xfG:|aYOgRZN{[Xl? MoXUN|Ah|ryP NGnYUlg2KGR? NVHH[oZz\GWlcnXhd4V{KGOnbHygdJJwdGmoZYLheIlwdg>? MlPtNlQzOTF{NUO=
7721 NILtNmJCeG:ydH;zbZMhSXO|YYm= MkfqN|Ah|ryP NX\ESGttPSCm M1LI[oRm[3KnYYPld{Bk\WyuIIDyc4xq\mW{YYTpc44> MnXFNlQzOTF{NUO=
SGC7901  NHXUOXdCeG:ydH;zbZMhSXO|YYm= MUW1NOKh|ryP NVLYZ2dJOjRxNEivO|IhcA>? MVjEUXNQ NES0dFVqdmS3Y3XzJIFxd3C2b4Ppd{Bkd22kaX7l[EB4cXSqIFrBT|Ihe2iUTlG= NGTXVZUzPDF5OEK0NC=>
SMMC7721 NHzEVYdHfW6ldHnvckBCe3OjeR?= NEXZeGszPS93MDFOwG0> NEnocHAzPCCq NVeyS|Rwe3WycILld5NmeyC2aHWg[ZhxemW|c3nvckBw\iCyLVHreEBweiCyLVXST|EwOsLi MmrkNlQyPjhyNU[=
MCF-7 M4\1dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrpXnoyOCEQvF2= MWe0PIg> MlzaSG1UVw>? Ml7FdoV3\XK|ZYOgRm5HNWmwZIXj[YQh[2WubDDjfYNt\SCjcoLld5Q> NIHWSJkzPDF4M{SwOC=>
Caco-2 NXj1d4xOTnWwY4Tpc44hSXO|YYm= NUjWdIhVPTEEoN88US=> NFHTPW81QGh? MnrWSG1UVw>? NYDjW2Rk\W6qYX7j[ZMhfGinIH3SUmEhdGW4ZXzzJI9nyqCVQ17ONWEtTli\REOsxsBNS1RuwrDMU3gtyqCKSV[zRUzDqFqJMU[sxsBRTEV4QdMgZY5lyqCOR1HMV|E3yqCpZX7ld:Kh[29vdILlZZRm\CC5aYToJGRmgA>? M321TVI1OTZzNkm1
HAECs NVX1Zot1TnWwY4Tpc44hSXO|YYm= MWKxNEDPxE1? NGL1OYgyKGh? MWpCpIF1fGWwdXH0[ZMhXE6ILd8xMZN1cW23bHH0[YQhUUODTT2xJIFv\CCYQ1HNMVEh\XiycnXzd4lwdg>? M3XLelI1OTN2NkW3
Ca9-22 NX7XOGR3TnWwY4Tpc44hSXO|YYm= M2XjOFMh|ryP M1z5blEhcA>? NGnwN3Fi[m:uaYPo[ZMhfGinIHHibYxqfHlib3[gTIJTKHSxIHnu[JVk\SCLTD24JJBzd2S3Y4Tpc44> MmnNNlQyOjZ3M{K=
Ca9-22 MXTGeY5kfGmxbjDBd5NigQ>? MXGzJO69VQ>? M1rMXlEwOiCq MV\y[YR2[2W|IFjiVk1qdmS3Y3XkJGFVTi1{IIDoc5NxcG:{eXzheIlwdg>? NXvXXod6OjRzMk[1N|I>
AGS MoC3SpVv[3Srb36gRZN{[Xl? NVntWnJZOTBizszNxsA> NUXYOXg6OC53IHi= MWPpcohq[mm2czD0bIUhfXC{ZXf1cIF1cW:wIH;mJJRp\SCLTD24JIdmdmV? M33ESlI1OTB4MU[2
Caco-2  M3fUN2Fxd3C2b4Ppd{BCe3OjeR?= MYKxNOKh|ryP M{nkV|I1yqCq NFjQRXll\WO{ZXHz[ZMh[2WubDDhdI9xfG:|aYOgbY5lfWOnZDDifUA2NU[X M2rzVlI1ODl3OE[z
HCT-8 MkDnRZBweHSxc3nzJGF{e2G7 MUCxNOKh|ryP MU[yOOKhcA>? NFHMZYpl\WO{ZXHz[ZMh[2WubDDhdI9xfG:|aYOgbY5lfWOnZDDifUA2NU[X MV[yOFA6PTh4Mx?=
A549 MWHGeY5kfGmxbjDBd5NigQ>? M1LwNVUxyqEQvF2= MVWyJIg> NEXSV2VjdG:la4OgSXJMKHCqb4PwbI9zgWyjdHnvckBu\WSrYYTl[EBjgSBzLEKtUnE> NGnBT5czPDB4N{eyOy=>
HPMC MX3GeY5kfGmxbjDBd5NigQ>? M4r5bFExyqEQvF2= Mn;uOFghcA>? MYjy[ZZmenOnczD0bIUh[2ijbnfld{BqdiClZXzsJI1wenCqb3zv[5khcW6mdXPl[EBjgSCKR2DEVy=> MXWyOFA1Ojh|OB?=
HPMC M2DlRmFxd3C2b4Ppd{BCe3OjeR?= M322NlExyqEQvF2= NIH1NngzPMLiaB?= M1\Ed5JmfmW{c3XzJIRm[3KnYYPlJIlvKGOnbHygeoli[mmuaYT5JIlv\HWlZXSgZpkhUEeSRGO= MmLxNlQxPDJ6M{i=
MGC803  MWXBdI9xfG:|aYOgRZN{[Xl? MX[yNOKh|ryP NGDZblQyKGh? NVrUS5lEcW6qaXLpeJMh[XCxcITvd4l{KGmwZIXj[YQh[nliSV\OMe6yyqCjbnSgOgKBui2GRmXS MonGNlQxOjd5NUC=
SGC7901 MYTBdI9xfG:|aYOgRZN{[Xl? NF3Rc40zOMLizszN MnfaNUBp MYrpcohq[mm2czDhdI9xfG:|aYOgbY5lfWOnZDDifUBKTk5vzsJCpIFv\CB34pEyMWRHXVJ? MXqyOFAzPzd3MB?=
COLO205 M3;BZ2Fxd3C2b4Ppd{BCe3OjeR?= NUjjVoY{OTBxMkCvOFAh|ryP MoL2NlQhcA>? NUfzOZVLcW6mdXPld{BFVkFibHHk[IVzKG[xcn3heIlwdg>? MVSyOFAyQTFyOB?=
G292  NX:wfGRPSXCxcITvd4l{KEG|c3H5 MWWzNOKh|ryP Mn7XNkBp NWfhdZhwemW|dH;y[ZMh[2Gyc3HpZ4lvNWmwZIXj[YQh[2WubDDk[YF1cA>? NInQR|YzPDBzMkmzNC=>
BxPC-3 MV\GeY5kfGmxbjDBd5NigQ>? M4XuU|ExKM7:TdMg MnrTOkBp NIPSTXRqdmO{ZXHz[UBucVJvMUSzJIV5eHKnc4Ppc44> NUTm[|RzOjN7N{O3NVA>
HPAF-II NVHieGhETnWwY4Tpc44hSXO|YYm= MVyxNEDPxE4EoB?= NVHaR2gyPiCq Mn\lbY5kemWjc3WgcYlTNTF2MzDlfJBz\XO|aX;u M171dlI{QTd|N{Gw
HL-60 MV3BdI9xfG:|aYOgRZN{[Xl? NWLxdY5rPTEEoN88US=> MV2xJIg> NULXXVNFemW|Y4Xld{BDSTF2NTDt[YRq[XSnZDDhdI9xfG:|aYO= M2TYN|I{QTR6N{Wx
HepG2 MkXKSpVv[3Srb36gRZN{[Xl? MmLaOFAh|ryP NXLSfnFsPi9zMjDo Ml3HbY5pcWKrdIOgeIhmKGmwY4LlZZNmKG:oIICtSXJMOSCjbnSgdE1kNUq3bjDwdo91\WmwIHX4dJJme3Orb36gZpkhWEx? NY[1VoRxOjN7NEK4OVE>
HUVECs M1TjOWZ2dmO2aX;uJGF{e2G7 NYfNdWJMOjVizszN NF65SYQyKGh? Ml74bY5kemWjc3WgUmYu|rqEIIC2OUBvfWOuZXHyJJRz[W6|bH;jZZRqd25? NIrjSZUzOzlyMUCwPC=>
LNCaP  NHTqPIpHfW6ldHnvckBCe3OjeR?= NUHSfnRROTBizszNxsA> NVHibFc6OSCq NHj1blVl\WO{ZXHz[ZMhfGinIFXHSkB2eHKnZ4XsZZRm\CCyLWnCMVE> NHrvdJYzOzh|OEOxPC=>
HL60  MXLGeY5kfGmxbjDBd5NigQ>? MVmyNOKh|ryP MU[3NkBp M1ixS2ROW09? M3j2OolvcGmkaYTzJIRie2G2aX7pZk1qdmS3Y3XkJGNFOTGkIHX4dJJme3Orb36= MUSyN|gzPTV6NR?=
NB4  MoHrSpVv[3Srb36gRZN{[Xl? MV:xNEDPxE4EoB?= NIDOfWs4OiCq M1fIeGROW09? NYq5WFF[cW6qaXLpeJMh\GG|YYTpcoljNWmwZIXj[YQhS0RzMXKg[ZhxemW|c3nvci=> NVTvW4hROjN6MkW1PFU>
EPOR/CR3 M{\Z[WZ2dmO2aX;uJGF{e2G7 M1XF[lUxyqEQvF2= MYCzJIg> NHfub5dz\WS3Y3XzJGVRVyCjbnSvc5IhUUxvMz3pcoR2[2WmIITo[UB1gXKxc3nu[UBxcG:|cHjvdplt[XSrb39CpC=> NXLoPXNQOjN6MkC3N|E>
HUASMCs NVXiTYhrTnWwY4Tpc44hSXO|YYm= NFTVdFgyOCEQvF5CpC=> M{DMbVI1KGh? NVK5NnE{\GmvaX7pd4hmeyCDbnegTWku[2G3c3XkJHNQS1N|IH3SUmEh[W6mIIDyc5RmcW5iZYjwdoV{e2mxbtMg MXuyN|gyPjR4OB?=
HUASMCs MmH5SpVv[3Srb36gRZN{[Xl? NXjsOXNVOTBizszNxsA> M4LGPFI1KGh? MoOwbY5pcWKrdIOgRY5oKEmLLXnu[JVk\WRiRWLLNU8zKHCqb4PwbI9zgWyjdHnvckBt\X[nbB?= NHe4fZgzOzhzNkS2PC=>
SGC7901 M3nYZ2Z2dmO2aX;uJGF{e2G7 M2TPOFExKM7:TdMg MWqyOEBp MV\pcohq[mm2czD0bIUh\XiycnXzd4lwdiCxZjDwbI9{eGixconsZZRm\CCHUluxM|I> NGCx[G8zOzd7MkW4PC=>
MKN45 NEfLcG1HfW6ldHnvckBCe3OjeR?= M1fTbVExKM7:TdMg MYqyOEBp M4TERolvcGmkaYTzJJRp\SCneIDy[ZN{cW:wIH;mJJBpd3OyaH;yfYxifGWmIFXST|EwOg>? M4DCXVI{Pzl{NUi4
SGC7901 MnzDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jsflExKM7:TdMg M3\K[|I1NzR6L{eyJIg> NELyXYdqdmirYnn0d{Bk\WyuIHfyc5d1cCClbz30doVifGWmIIfpeIghTEGSVB?= NV7WUWt4OjN5OUK1PFg>
MKN45 M2DZTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;BV212OTBizszNxsA> M4PqfVI1NzR6L{eyJIg> MX3pcohq[mm2czDj[YxtKGe{b4f0bEBkdy22cnXheIVlKHerdHigSGFRXA>? MXOyN|c6OjV6OB?=
SGC7901 NE[3WYpCeG:ydH;zbZMhSXO|YYm= MVixNEDPxE4EoB?= M{DrOFI1KGh? NIr4UJlqdmO{ZXHz[ZMhfGinIFTBVHQucW6mdXPl[EBk\WyuIHHwc5B1d3Orcx?= M1Oyb|I{Pzl{NUi4
MKN45 M4nmPWFxd3C2b4Ppd{BCe3OjeR?= MVexNEDPxE4EoB?= Ml\sNlQhcA>? NU\kUlJjcW6lcnXhd4V{KHSqZTDERXBVNWmwZIXj[YQh[2WubDDhdI9xfG:|aYO= NGnvN5AzOzd7MkW4PC=>
BxPC-3 cells MmnSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn[4NlDDqM7:TR?= NWT5clRDOC53IHi= NHTUZ5BqdmirYnn0d{BXTUeILVGtdoVofWyjdHXkJGhWXkWFIHfyc5d1cCCjbnSgeJVj\SCob4LtZZRqd25iaX7keYNm\CCkeTDQRXIuOiCDUB?= MoH2NlM4PjRyNE[=
NB4  NULS[IF4SXCxcITvd4l{KEG|c3H5 MYexNE8zOC94MDFOwG0> NXzRdolKOS53IHi= MVzEUXNQ M{nJbIRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDjc{11emWjdHXkJJdqfGhiUHHjcIl1[XinbB?= NVTjS4FROjN5M{W1OFE>
HepG2  NYHYeGZLTnWwY4Tpc44hSXO|YYm= MXuyNOKh|ryP NGPvWVczPCCq MY\pcohq[mm2czD0bIUhUE9vMTDwdo91\WmwIHX4dJJme3Orb36gZ48ufHKnYYTl[EB4cXSqIH3leIZwem2rbh?= M3rXNFI{PzB5NkC5
HUVECs NWDjdnB{SXCxcITvd4l{KEG|c3H5 MUGyM|Qh|ryP MnnsNlQwPDhiaB?= NW\NTIlucW6mdXPld{Bk\WyuIHTlZZRp M1K2VVI{PzB5NUKw
KG-1  Mn\GRZBweHSxc3nzJGF{e2G7 M1fPPFIxyqEQvF2= M4XaUFEzKGh? Mk\u[Y5p[W6lZYOgZ4VtdCCjcH;weI9{cXNiaX7keYNm\CCkeTDTNS=> NYS1SoZFOjN5ME[2PVE>
AML 1# MXPBdI9xfG:|aYOgRZN{[Xl? NEjCNXIzOMLizszN MorONVIhcA>? MoPm[Y5p[W6lZYOgZ4VtdCCjcH;weI9{cXNiaX7keYNm\CCkeTDTNS=> NFvlZ3MzOzdyNk[5NS=>
A2780  NYjYeVR2TnWwY4Tpc44hSXO|YYm= NHzmWGgzOMLizszN MWexJIg> MkWxZoxw[2u|IFTUR2QucW6mdXPl[EBFWjViZYjwdoV{e2mxbh?= MWWyN|Y6Pjh4Mh?=

... Click to View More Cell Line Experimental Data

In vivo Treatment of mice 30 minutes before focal cerebral ischemia with PD98059 protects against damage, resulting in a decrease in infarct volume. [5] Pretreated with PD98059 (10 mg/kg per i.v. injection) 30 minutes before and then together with hourly cerulein injections for 3 hours significantly ameliorates cerulein-induced acute pancreatitis ipancreatitis on the basis of pancreatic wet weight and histology. [6] Administration of PD98059 (10 mg/kg) in mice 1 hour after carrageenan causes a reduction in all the parameters of inflammation measured. [7]

Protocol

Kinase Assay:

[1]

+ Expand

In vitro MEK-inhibitory activity:

Incorporation of 32P into myelin basic protein (MBP) is assayed in the presence of glutathione S-transferase (GST) fusion proteins containing the 44-kDa MAPK (GST-MAPK) or the 45-kDa MEK (GST-MEK1). Assays are conducted in 50 μL of 50 mM Tris, pH 7.4/10 mM MgCl2/2 mM EGTA/10 μM [γ-32P]ATP containing 10 μg of GST-MEK1, 0.5 μg of GST-MAPK, and 40 μg of MBP. After incubation at 30°C for 15 minutes, reactions are stopped by addition of Laemmli SDS sample buffer. Phosphorylated MBP is resolved by SDS/10% PAGE.
Cell Research:

[1]

+ Expand
  • Cell lines: K-Balb, KNRK, v-raf-3Y1, SRA/3Y1, EGFR/3T3, and K562
  • Concentrations: Dissolved in DMSO, final concentrations ~100 μM
  • Incubation Time: 3 dyas, or 7-10 days
  • Method:

    For monolayer growth, cells are plated into multi-well plates at 10,000-20,000/mL. Forty-eight hours later, various concentrations of PD98059 are added to the cell growth medium and incubation is continued for an additional 3 days. Cells are then removed from the wells by incubation with trypsin and enumerated with a Coulter Counter. For growth in soft agar, cells are seeded into 35-mm dishes at 5,000-10,000 cells per dish with growth medium containing 0.3% agar and desired concentrations of PD98059. After 7-10 days of growth, visible colonies are manually enumerated with the aid of a dissecting microscope.


    (Only for Reference)
Animal Research:

[7]

+ Expand
  • Animal Models: Male Sprague–Dawley rats with acute pancreatitis
  • Formulation: Dissolved in DMSO, and diluted in saline
  • Dosages: 10 mg/kg
  • Administration: Injection i.v.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 14 mg/mL warmed (52.37 mM)
Water slightly soluble or insoluble
Ethanol slightly soluble or insoluble
In vivo 4% DMSO+30% PEG 300+5% Tween 80+ddH2O 1mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 267.28
Formula

C16H13NO3

CAS No. 167869-21-8
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

MEK Signaling Pathway Map

MEK Inhibitors with Unique Features

Related MEK Products

Tags: buy PD98059 | PD98059 supplier | purchase PD98059 | PD98059 cost | PD98059 manufacturer | order PD98059 | PD98059 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID